Status:

UNKNOWN

Effect of Hyperuricaemia on Chronic Renal Disease

Lead Sponsor:

The Affiliated Hospital of Xuzhou Medical University

Collaborating Sponsors:

The First People's Hospital of Xuzhou

Conditions:

Hyperuricemia

Chronic Renal Disease

Eligibility:

All Genders

18-70 years

Phase:

PHASE4

Brief Summary

To investigate the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention

Detailed Description

This study aims to explore the best effective dose and adverse reaction of febuxostat in lowering serum uric acid to low level in patients with Chronic Renal Disease at different stages. To elucidate ...

Eligibility Criteria

Inclusion

  • Non-dialysis CKD patients with serum uric acid greater than 7mg/dl.
  • eGFR≥15ml/min/1.73m².
  • Low salt, low protein, low purine diet.

Exclusion

  • Take drugs that raise blood uric acid at the same time.
  • Patients with gout attacks.
  • Patients with pregnant, lactating.
  • Autosomal dominant polycystic kidney disease.
  • Patients with poor general condition and multiple organ failure.

Key Trial Info

Start Date :

January 1 2017

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2018

Estimated Enrollment :

400 Patients enrolled

Trial Details

Trial ID

NCT03425708

Start Date

January 1 2017

End Date

December 31 2018

Last Update

February 7 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China, 221000